$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Follows Promising Recent Clinical Data
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
